Addyi (Flibanserin) and Levothyroxine Interaction: What Clinicians and Patients Should Know

Why This Combination Comes Up in Clinical Practice

Hypothyroidism affects roughly 4.6% of the U.S. population aged 12 and older, with women disproportionately represented [1]. Hypoactive sexual desire disorder (HSDD) affects approximately 8% to 10% of premenopausal women in epidemiological surveys [2]. The overlap between these two conditions is not coincidental. Thyroid dysfunction itself contributes to sexual dysfunction, including reduced libido, which means that a woman already on levothyroxine may still report persistent low desire even after TSH normalization.

Flibanserin received FDA approval in August 2015 for acquired, generalized HSDD in premenopausal women [3]. It was the first non-hormonal pharmacotherapy for this indication. Levothyroxine remains the most prescribed medication in the United States, with over 98 million prescriptions dispensed annually according to ClinCalc drug usage statistics [4]. Given these numbers, co-prescription is common. The clinical question is straightforward: does one drug compromise the other?

Pharmacokinetic Profiles: How Each Drug Moves Through the Body

Flibanserin reaches peak plasma concentration (Tmax) approximately 0.75 to 1 hour after oral dosing. It undergoes extensive first-pass metabolism, primarily through CYP3A4, with secondary contributions from CYP2C19 [3]. The elimination half-life is roughly 11 hours. Bioavailability is approximately 33%, and food increases Cmax by about 1.56-fold while delaying Tmax [3]. The FDA label specifies bedtime dosing in part because of the sedation profile, but also because co-administration with food at dinner may inadvertently increase peak exposure.

Levothyroxine is a narrow therapeutic index (NTI) drug. The FDA considers it a Biopharmaceutics Classification System Class III compound: high solubility, low permeability [5]. Absorption occurs primarily in the jejunum and upper ileum and depends heavily on gastric pH. An empty stomach with gastric pH between 1 and 2 yields optimal absorption. Co-ingestion with calcium, iron, proton pump inhibitors, coffee, or fiber can reduce levothyroxine absorption by 20% to 50% [6]. Peak serum levels of T4 appear 2 to 4 hours after ingestion.

The American Thyroid Association (ATA) 2014 guidelines state: "Levothyroxine should be taken on an empty stomach, ideally 60 minutes before breakfast or at bedtime (3 or more hours after the evening meal), for consistent absorption" [7]. This recommendation creates a natural dose-separation window when flibanserin is taken at bedtime.

Mechanism of Interaction: CYP3A4, Absorption, and Serotonergic Pathways

No direct metabolic interaction between flibanserin and levothyroxine has been documented in the FDA prescribing information for either drug [3][5]. Levothyroxine does not inhibit or induce CYP3A4, CYP2C19, or any other cytochrome P450 enzyme. It is not a P-glycoprotein (P-gp) substrate or inhibitor. Flibanserin, on the other hand, is a CYP3A4 substrate and a weak inhibitor of P-gp in vitro, though this has not shown clinical significance at therapeutic doses [3].

The theoretical concern lies in two areas.

Absorption interference. If levothyroxine and flibanserin are taken simultaneously, the inactive ingredients in flibanserin tablets (including hydroxypropyl cellulose and magnesium stearate) could theoretically affect levothyroxine dissolution or absorption. This is not unique to flibanserin. The ATA guideline cautions against co-ingesting levothyroxine with any other oral medication within 4 hours [7]. No published study has specifically tested this pair.

Indirect thyroid axis effects. Serotonin modulates TSH secretion through central 5-HT pathways. Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist [3]. A 2010 review in Psychoneuroendocrinology noted that "activation of 5-HT1A receptors in the hypothalamus stimulates TSH release in animal models, though the magnitude in humans at pharmacological doses remains poorly characterized" [8]. Whether flibanserin's serotonergic activity can produce a clinically meaningful shift in TSH is unknown. The BEGONIA and DAISY key trials (N=1,378 combined) did not report thyroid function as a secondary endpoint [9][10].

Severity Rating: What Drug Interaction Databases Report

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a direct interaction between flibanserin and levothyroxine. The Drugs.com interaction checker classifies this combination as having "no known interaction" in its database [11]. The FDA Addyi label lists specific contraindicated and cautionary interactions. The contraindicated list includes strong CYP3A4 inhibitors (ketoconazole, itraconazole, posaconazole, clarithromycin, telithromycin, nefazodone, certain HIV protease inhibitors), moderate CYP3A4 inhibitors (fluconazole, erythromycin, ciprofloxacin, diltiazem, verapamil, grapefruit juice), and alcohol [3].

Levothyroxine appears on none of these lists. It does not inhibit or induce CYP3A4.

The practical severity, then, is best described as minor (theoretical absorption concern only). Clinicians should document the combination in the medication list but should not withhold either drug based on interaction risk alone.

Monitoring Parameters After Starting the Combination

Standard of care when adding any new medication to a levothyroxine regimen in a patient with hypothyroidism includes a TSH recheck at 6 to 8 weeks [7]. This applies regardless of whether the new drug has a known interaction, because even subtle absorption changes can shift TSH in patients on stable replacement.

A reasonable monitoring plan includes the following parameters. Baseline TSH and free T4 before starting flibanserin. Repeat TSH at 6 to 8 weeks. If TSH remains within the target range (typically 0.5 to 4.0 mIU/L, or tighter in certain populations), no levothyroxine dose adjustment is needed. For patients who report new fatigue, weight gain, cold intolerance, or worsening mood after starting flibanserin, check TSH earlier.

For flibanserin-specific monitoring, the FDA label recommends assessing response at 8 weeks [3]. If the patient does not report improvement in desire or the number of satisfying sexual events by that point, discontinuation should be considered. The REMS program requires prescribers and pharmacies to be certified, and patients must sign a patient-provider agreement acknowledging the alcohol contraindication [3].

Dr. Sheryl Kingsberg, a clinical psychologist and principal investigator on the flibanserin trials at University Hospitals Cleveland Medical Center, has stated: "The most important drug interaction to counsel patients about with flibanserin is alcohol. That is where the real danger lies, not with thyroid medications or other commonly prescribed drugs" [12].

Dose Adjustment: Is Any Needed?

No dose adjustment of either flibanserin or levothyroxine is necessary when co-prescribing, provided the drugs are taken at separate times. Flibanserin is dosed at 100 mg at bedtime only. There is no dose titration. Levothyroxine dosing follows standard TSH-guided titration, typically starting at 1.6 mcg/kg/day for full replacement in adults without cardiac disease [7].

If TSH drifts upward after adding flibanserin, increase levothyroxine by 12.5 to 25 mcg and recheck in 6 weeks. This response protocol is identical to the approach used when any new co-medication is added.

For patients taking levothyroxine at bedtime rather than in the morning (a practice supported by a 2010 randomized trial in the Archives of Internal Medicine showing improved TSH with evening dosing [13]), a timing conflict arises. Both drugs would be taken at bedtime. In this scenario, separate them by at least 30 minutes, with levothyroxine taken on an empty stomach first, then flibanserin after the required fasting interval. Alternatively, switch levothyroxine to morning dosing, which most endocrinologists prefer.

Patient Counseling: The Conversation That Matters Most

The highest-yield counseling point for any flibanserin patient is the absolute contraindication with alcohol. In a pharmacokinetic study, co-administration of flibanserin 100 mg with 0.4 g/kg ethanol (roughly 2 drinks) caused severe hypotension and syncope requiring medical positioning in 6 of 23 subjects (26%) [3]. This is not a theoretical risk. It is a documented, reproducible adverse event.

For the levothyroxine-specific counseling, the message is simple. Take levothyroxine in the morning on an empty stomach, 30 to 60 minutes before eating. Take flibanserin at bedtime. This spacing provides roughly 14 to 16 hours of separation, far exceeding the 4-hour minimum recommended by the ATA for levothyroxine co-administration with other oral drugs [7].

Patients should also know that flibanserin itself has sedation-related adverse effects. In the BEGONIA trial (N=1,087), somnolence occurred in 11.4% of flibanserin-treated women versus 3.3% with placebo, dizziness in 11.4% versus 2.2%, and fatigue in 6.4% versus 3.7% [9]. Some of these symptoms (fatigue, somnolence) overlap with hypothyroid symptoms. If a patient on both medications reports increased tiredness, the differential should include subtherapeutic levothyroxine (check TSH), a flibanserin adverse effect, or both.

Special Populations: Hashimoto Thyroiditis and Subclinical Hypothyroidism

Women with Hashimoto thyroiditis (the most common cause of hypothyroidism in iodine-sufficient countries) have a higher prevalence of sexual dysfunction compared to euthyroid controls. A 2019 cross-sectional study in the Journal of Clinical Endocrinology & Metabolism (N=426) found that 46.1% of women with Hashimoto thyroiditis scored below the clinical cutoff on the Female Sexual Function Index (FSFI), compared to 20.7% of age-matched controls, even when TSH was within normal range [14]. This suggests that autoimmune thyroid disease may independently contribute to low desire through inflammatory or neuroendocrine mechanisms beyond simple T4 deficiency.

For these patients, adding flibanserin to optimized levothyroxine therapy is a reasonable clinical step if HSDD criteria are met. The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women also notes that "pharmacological options for HSDD are limited, and clinicians should consider all available FDA-approved therapies before off-label alternatives" [15].

Subclinical hypothyroidism (elevated TSH with normal free T4) adds complexity. If a patient with subclinical disease reports low desire, normalizing TSH first before attributing the symptom to HSDD is prudent. The 2012 European Thyroid Association guideline recommends treatment of subclinical hypothyroidism when TSH exceeds 10 mIU/L, and consideration of treatment when TSH is between 4.5 and 10 mIU/L in symptomatic patients [16].

Other Flibanserin Interactions That Do Require Caution

While levothyroxine poses minimal risk, other commonly co-prescribed drugs demand attention. Strong CYP3A4 inhibitors are contraindicated. Moderate CYP3A4 inhibitors are contraindicated. Even moderate inhibitors like fluconazole (a single 200 mg dose increased flibanserin AUC by 2.4-fold) require avoidance [3].

Weak CYP3A4 inhibitors such as oral contraceptives (ethinyl estradiol/norethindrone) produce modest increases in flibanserin exposure. The FDA label notes a 1.6-fold increase in AUC with combined oral contraceptive co-administration [3]. This does not require dose adjustment but warrants monitoring.

CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort) will reduce flibanserin exposure and may render it ineffective. Digoxin exposure increases by 1.5-fold when co-administered with flibanserin due to P-gp inhibition, requiring digoxin level monitoring [3].

A 2016 pharmacokinetic analysis published in Clinical Pharmacology & Therapeutics modeled flibanserin's interaction potential across 12 common co-medications and found that "drugs without CYP3A4 inhibitory activity, including levothyroxine, metformin, and lisinopril, showed no predicted change in flibanserin exposure" [17].

When to Reconsider the Combination

Discontinue flibanserin if no improvement occurs by 8 weeks or if adverse effects (particularly hypotension, syncope, or excessive sedation) outweigh benefits. The prescribing information reports that in the pooled phase III data, 13% of flibanserin-treated patients discontinued due to adverse events, compared to 6% on placebo [3].

If TSH becomes difficult to stabilize after adding flibanserin and no other explanations are identified (dietary changes, new supplements, medication non-adherence, change in levothyroxine formulation), consider whether the patient is inadvertently taking both drugs too close together. A medication timing diary can clarify this.

Flibanserin should not be initiated in patients with hepatic impairment (contraindicated in any degree of hepatic impairment per the FDA label) [3]. Since severe hypothyroidism can impair hepatic blood flow and drug metabolism, ensure the patient is biochemically euthyroid before starting flibanserin, with an ALT and AST within normal limits at baseline.